Table 1.
Characteristics of nonelderly and elderly patients with gastric cancer receiving ESD
| Total patients (n = 10,320) | Nonelderly patients, younger than 80 yr (n = 8,645) | Elderly patients, older than 80 yr (n = 1,675) | P | |
| Demographic | ||||
| Age, yr, mean ± SE | 71.7 ± 9.1 | 69.3 ± 7.9 | 83.9 ± 2.6 | <0.001 |
| Men, n (%) | 7,660 (74.2) | 6,533 (75.6) | 1,127 (67.3) | <0.001 |
| Comorbidities | ||||
| Ischemic heart disease, n (%) | 730 (7.1) | 550 (6.4) | 180 (10.7) | <0.001 |
| Liver cirrhosis, n (%) | 192 (1.9) | 158 (1.8) | 34 (2.0) | 0.575 |
| Hemodialysis, n (%) | 155 (1.5) | 115 (1.3) | 40 (2.4) | 0.001 |
| AT therapy, n (%) | 1,860 (18.0) | 1,376 (15.9) | 484 (28.9) | <0.001 |
| APA, n (%) | 1,428 (13.8) | 1,041 (12.0) | 387 (23.1) | <0.001 |
| Aspirin, n (%) | 981 (9.5) | 722 (8.4) | 259 (15.5) | <0.001 |
| Cilostazol, n (%) | 236 (2.3) | 166 (1.9) | 70 (4.2) | <0.001 |
| Thienopyridine, n (%) | 460 (4.5) | 345 (4.0) | 115 (6.9) | <0.001 |
| Anticoagulant drug, n (%) | 579 (5.6) | 445 (5.1) | 134 (8.0) | <0.001 |
| Warfarin, n (%) | 326 (3.2) | 238 (2.8) | 88 (5.3) | <0.001 |
| DOAC, n (%) | 253 (2.5) | 207 (2.4) | 46 (2.7) | 0.394 |
| Interruption of AT agents, n (%) | 1,406 (13.6) | 1,034 (12.0) | 372 (22.2) | <0.001 |
| One kind of AT agent, n (%) | 1,215 (11.8) | 887 (10.3) | 328 (19.6) | <0.001 |
| Two kinds of AT agent, n (%) | 181 (1.8) | 1,422 (1.6) | 39 (2.3) | |
| Three kinds of AT agent, n (%) | 10 (0.1) | 5 (0.1) | 5 (0.3) | |
| Replacement of APAs, n (%) | 121 (1.2) | 83 (1.0) | 38 (2.3) | <0.001 |
| Heparin bridging, n (%) | 429 (4.2) | 322 (3.7) | 107 (6.4) | <0.001 |
| Lesion | ||||
| Multiple tumors, n (%) | 1,294 (12.5) | 1,053 (12.2) | 241 (14.4) | 0.013 |
| Location in lower third of stomach, n (%) | 4,688 (45.4) | 3,860 (44.7) | 828 (49.4) | <0.001 |
| Predominance of undifferentiated type, n (%) | 506 (4.9) | 469 (5.4) | 37 (2.2) | <0.001 |
| Tumor size, mm, mean ± SE | 17.7 ± 12.5 | 17.4 ± 12.2 | 19.4 ± 13.9 | <0.001 |
| Invasion to SM2, n (%) | 655 (6.3) | 535 (6.2) | 120 (7.2) | 0.134 |
| Ulceration (scar), n (%) | 977 (9.5) | 813 (9.4) | 164 (9.8) | 0.631 |
| Procedure | ||||
| Procedure time >120 min, n (%) | 1,886 (18.3) | 1,570 (18.2) | 316 (19.0) | 0.453 |
| En block resection, n (%) | 10,261 (99.4) | 8,599 (99.5) | 1,662 (99.2) | 0.225 |
| Second-look endoscopy, n (%) | 7,384 (71.6) | 6,128 (70.9) | 1,256 (75.0) | 0.001 |
| Use of antacid drug (PPI/P-CAB/H2RA), n (%) | 10,303 (99.8) | 8,632 (99.8) | 1,671 (99.8) | 0.414 |
| Bleeding, n (%) | 489 (4.7) | 393 (4.5) | 96 (5.7) | 0.037 |
| Perforation, n (%) | 154 (1.5) | 127 (1.2) | 27 (1.6) | 0.802 |
| Hospital stay duration, d, mean ± SE | 7.0 ± 4.0 | 6.9 ± 3.7 | 7.5 ± 5.2 | <0.001 |
P: statistical difference between nonelderly and elderly patients.
APA, antiplatelet agent; AT, antithrombotic; DOAC, direct oral anticoagulant; ESD, endoscopic submucosal dissection; H2RA, histamine 2 receptor antagonist; P-CAB, potassium-competitive acid blocker; PPI, proton pump inhibitor; SM2, submucosal invasion ≥500 μm from the muscularis mucosa.